Roche moved to end two Huntington’s disease trials tied to Ionis, discontinuing the Phase 2 GENERATION HD2 study of tominersen after the asset failed its key efficacy objective, and also stopping a separate RG6496 program after new animal data. The company said the decisions are data-driven and that it and Ionis will continue other partnered programs. Roche’s action lands amid additional Ionis setbacks. Separate from Huntington’s, Ionis reported that its AstraZeneca-partnered Wainua failed the Phase 3 CARDIO-TTRansform trial in transthyretin amyloidosis cardiomyopathy—an outcome that has amplified scrutiny of knockdown-and-stabilization strategies in ATTR-CM. Shares of Ionis were reported to have fallen sharply on the latest news. For drug developers, the combined readouts sharpen the debate over whether overlapping biological mechanisms or the antisense modality itself is limiting efficacy in TTR amyloid cardiomyopathy, even when target lowering is achieved. More broadly, the Roche-Ionis decision underscores how quickly antisense programs can be pruned after efficacy disappointments.